|
GSK PLC on Tuesday said it is ending the development programme for monoclonal antibody belrestotug. Shares in GSK were down 1.3% to 1,381.00 pence in London on Tuesday afternoon. The London-based pharmaceutical company said belrestotug is an anti-TIGIT monoclonal antibody it was developing alongside partner iTeos Therpaeutics Inc. GSK said the decision to end the development is based on interim analyses from the phase 2 Galaxies Lung-201 and H&N-202 studies, which ‘did not meet the established efficacy criteria for continued development’. It said the collaboration and all belrestotug-containing study cohorts are ending as a result. The drug was being developed as a potential treatment for various cancers. GSK said it is expanding from its current focus on blood and women’s cancers into lung and gastrointestinal cancers, as well as other solid tumours. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
